PDB51 Resource Utilization in the Management of Acromegaly: An Analysis From Southwest Ontario  by Petrella, R.J. et al.
(year of marketing approval) of OADs. Using observations for 10 years and five
regions, it was possible to estimate a multiple regression model explaining sepa-
rately hospitalizations and hospital costs attributable to diabetes by regional fixed
effects, treated prevalence and the average vintage of OADs. RESULTS: The
results showed that the number of hospitalizations attributable to diabetes are
proportional to the treated prevalence, all else constant, but that the more recent
the OADs used (higher vintage), the lower are hospital admissions (p0.03) and
hospital costs (p0.007). According to the model, if the average vintage of OADs
had increased by one year, the number of admissions would have had a 3.8%
reduction (3965 less episodes in 2009) and hospital costs would have suffered a 5.3%
reduction (about 11 M€ in 2009). CONCLUSIONS: The possible influence of other
difficult to quantify factors notwithstanding, our analysis suggests that in the last
decade the availability of new OADs in the Portuguese market may have played a
key role in the reduction of hospital costs and in-patient admissions attributable to
diabetes.
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OBJECTIVES: Limited data exist on the use of health care resources due to hypo-
glycaemia induced by antidiabetic treatment. This study investigated the occur-
rence of self-reported non-severe hypoglycaemic events (NSHE) in type 1 (T1) and
insulin-treated type 2 (T2) diabetes patients and their impact on health care re-
source use. METHODS: Insulin-treated T1 and T2 patients from Austria, Denmark,
Finland, The Netherlands, Norway, Sweden and Switzerland were invited, primar-
ily via online panels, to complete four questionnaires at weekly intervals. Data
were collected on patient demographics, occurrence of NSHE in the last seven days
and hypoglycaemia-related resource use. NSHE was defined as an event with
symptoms of hypoglycaemia, with or without blood glucose measurement (BGM),
or low BGM without symptoms, which the patient could manage without
assistance. RESULTS: In total, 3958 patients with diabetes entered the study (57%
completing all four questionnaires). T1 and T2 patients experienced a mean of 1.7
and 0.5 events/pt-week. Overall employment rate was 48%. Following the last
NSHE, the proportion of patients contacting a health care professional was 8%
among T2 patients (Austria: 10%, Denmark: 7%, Finland: 10%, Norway: 6%, The
Netherlands: 8%, Sweden: 6%, Switzerland: 14%) and 2% among T1 patients (Aus-
tria: 3%, Denmark: 1%, Finland: 3%, Norway: 2%, The Netherlands: 3%, Sweden: 1%,
Switzerland: 5%). There was a mean increase in BG test use in the week following
the last NSHE of 1.9 across countries (Austria: 2.6, Denmark: 1.3, Finland: 2.1, The
Netherlands: 2.0, Norway: 1.8, Sweden: 1.5, Switzerland: 1.9). Among employed
patients, loss of work-time after the last hypoglycaemic event was reported by 10%
(Austria: 10%, Denmark: 9%, Finland: 17%, The Netherlands: 11%, Norway: 9%, Swe-
den: 12%, Switzerland: 6%). Between countries the average work-time loss among
those losing work-time ranged from 1.3 to 6.7 hours. CONCLUSIONS: NSHE were
associated with use of health care resources and work-time loss in the countries
studied.
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OBJECTIVES: To estimate the health care resource utilization and costs associated
with the management of patients with acromegaly in Québec. METHODS: A retro-
spective cohort study was conducted using data from the Quebec public health
plan (RAMQ) for the period from January 2001 to June 2011. Patients with at least
two diagnosis of acromegaly (ICD92530) reported by an endocrinologist or an
internist were selected. Characteristics of the study population are described in
terms of age, gender and co-morbidities. Health care resources utilization was
estimated, in terms of medical/surgical services, hospitalization, emergency visits
and medications. Costs of these resources were estimated annually over a three-
year period from the time of diagnosis of acromegaly and from the time of specific
intervention (transsphenoidal surgery (TSS) or medical treatment). RESULTS: A
total of 655 patients had at least diagnosis of acromegaly on two occasions reported
by an endocrinologist or an internist. Average age was 49.0(SD19.1) and 55.4%
were females. A pituitary adenoma was reported in 27.0% of patients. During the
study period, TSS was performed for 20.3% of patients while 19,7% had a medical
treatment. Medical therapy included bromocriptine (9.2%), cabergoline (7.6%), oc-
treotide (7.2%), lanreotide (0.5%) and pegvisomant (0.3%). Annual costs for all pa-
tients were $7,203(SD$12,706), $5,038(SD9,545) and $5,266(SD12,291) respec-
tively for each of the three year following initial acromegaly diagnosis. For patients
who had a TSS or a medical treatment, or a combination of these, total cost in the
first year following the initial intervention varies from $9,925 to $17,813. The most
frequent comorbidities were diabetes (47.6%) and hypertension (42.7%). Sleep ap-
nea and carpal tunnel syndrome were reported in 11.1% and 5.3% of patients re-
spectively Average annual costs of medications for the treatment of comorbidities
were $1,454(SD3,338). CONCLUSIONS: Results of this analysis of the RAMQ database
illustrate the significant economic burden of acromegaly and of its comorbidities.
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OBJECTIVES: To estimate the health care resource utilization and costs associated
with Cushing’s disease (CD) in Québec. METHODS: A retrospective cohort study
was conducted using data from the Quebec public health plan (RAMQ) from Janu-
ary 2001 to June 2011. Patients with at least two CD diagnoses (ICD92550) were
initially selected. CD was further confirmed with at least 2 diagnoses of CD reported
by an endocrinologist, or a diagnosis of pituitary adenoma, or a transsphenoidal
surgery (TSS) or a bilateral adrenalectomy (BLA). Health care resources comprise
medical/surgical services, hospitalization, emergency visits and medications.
Costs of these resources were estimated annually over a three-year period from the
time of diagnosis of CD and from the time of specific intervention (TSS, BLA or
medical treatment). RESULTS: Of the 810 patients with two diagnoses of CD, 322
were considered confirmed cases of endogenous CD. The average age was 48.0yrs
(SD16.8) and 72.0% were females. During the study period, TSS and BLA were
performed for 23% and 21.1% of patients respectively while 11.8% had a medical
treatment to control hypercortisolism. Among these patients 5.9% had two inter-
ventions and 0.9% had the three interventions. Annual costs for all patients were
$14,451, $5,737 and $5,679 respectively for each of the three year following initial
CD diagnosis. For patients who had a TSS, or a BLA, or a medical treatment, or a
combination of these, total cost in the first year following the initial intervention
varied from $12,258 to $28,888. The most frequent comorbidities were diabetes
(58.4%), hypertension (57.8%), and osteoporosis (51.2%). Patients had numerous
comorbidities; 85.1% had 2 or more and 69.0% 3 or more. Average annual costs of
medications for the treatment of comorbidities were $2,252 (SD5,713).
CONCLUSIONS: Results of this analysis of the RAMQ database illustrate the signif-
icant economic burden of CD and of its comorbidities.
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OBJECTIVES: To examine the demographic and clinical characteristics in patients
with Cushing’s disease (CD) and to estimate the health care resource utilization
associated in these patients in Ontario. METHODS: Retrospective analysis of re-
source use captured in the Southwestern Ontario Database from 2001 to June 2011.
A total of 86 patients (72% females) were analyzed based on diagnosis, out of a total
population of 523,718 patients. A matched control group (CG) (N86) was also
included from the general population. RESULTS: Age of patients at the time of
diagnosis was 4325.4 years (mean  SD). Baseline co-morbidities (CM) included
hypertension (67.4%), dyslipidemia (25%), diabetes (23.3%), renal calculi (17.4%),
visual disturbance (20.9%), carpal tunnel syndrome (19.8%) and osteoporosis
(11.6%). Distribution of co-morbidities was statistically significantly higher than
general population (p-value 0.05); 27% had 2 CM and 35% had 3 or more CM.
Baseline Urinary Free Cortisol (UFC) level was 207.7 118.3 nmol/day (UFC ULN
110 nmol/day). Primary treatment options included transsphenoidal surgery (TSS),
bilateral adrenalectomy (BLA), radiosurgery and medical therapy, used in 79%, 6%,
2.3% and 12.7% of patients respectively. Secondary treatment was surgical in 37% of
patients: consisting of repeat TSS in 21%, BLA in 10% and RS in 6%, while the
majority received medical therapy (63%). Average length of stay for surgery was 6
days (SD4) and 9 days (SD7) for TSS and BLA respectively. Medical therapy,
prescribed as monotherapy, included ketoconazole (38%), cabergoline (21%), bro-
mocriptine (20%) and mitotane (15%). Health care provider interactions per year for
CD post intervention compared to CG were: Emergency Room visit: 1.01 vs. 0.069;
clinic visits: 4.86 vs. 1.89; specialist clinic visits: 5.57 vs. 0.92; and hospitalizations:
0.34 vs. 0.15.CONCLUSIONS:This retrospective analysis of patients diagnosed with
Cushing’s disease indicates that they require substantially higher resource use and
experience a high burden of comorbidities.
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OBJECTIVES: To examine the demographic and clinical characteristics in patients
with acromegaly and to estimate the health care resource utilization associated in
these patients in Ontario. METHODS: Retrospective analysis of resource use cap-
tured in the Southwestern Ontario Database from 2001 to June 2011. A total of 131
patients (56% males) were analyzed based on diagnosis, out of a total population of
523,718 patients. A matched control group (CG) (N131) was also included from the
general population. RESULTS: Age of patients at the time of diagnosis was 3525.3
years (mean  SD). Primary treatment options included transsphenoidal surgery
(TSS), radiosurgery and medical therapy, used in 38%, 6% and 56% respectively.
Secondary treatment was surgical in 70% of patients: consisting of repeat TSS in
61% and RS in 9%, while 30% received medical therapy. Average length of stay for
surgery was 88 days in first line TSS. Most frequent post operative complications
(50%) was metabolic-related (81%), gastrointestinal (62%) and fever (38%). Medical
therapy, prescribed as monotherapy, included octreotide (47%), lanreotide (33%),
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pegvisomant (13%) and bromocriptine (7%). Baseline co-morbidities (CM) included
hypertension (66%), carpal tunnel syndrome (23%), osteoporosis (16%), dyslipide-
mia (12%), visual disturbance (12%), sleep apnea (2%), myocardial infarction (2%)
and renal calculi (2%). Distribution of co-morbidities was statistically significantly
higher than general population (p-value 0.05); specifically those with 1 CM (41%)
or 3 CM (19%) or more. Longitudinal assessment of co-morbidities reported no
statistically significant difference prior and post therapy. CONCLUSIONS: This ret-
rospective analysis of patients diagnosed with acromegaly indicates that they re-
quire substantially higher resource use and experience a high burden of comor-
bidities.
DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes & Patient
Preference Studies
PDB52
ADHERENCE: A REAL WORLD RETROSPECTIVE DATABASE STUDY AMONG TYPE
2 DIABETES PATIENTS TREATED WITH LIRAGLUTIDE OR EXENATIDE
Maria M1, Carlqvist P2, Langer J3, Bouchard J3
1Evidence Development Ltd., Stockholm, Sockholm, Sweden, 2Heron AB, Stockholm, Stockholm,
Sweden, 3Novo Nordisk, Inc., Princeton, NJ, USA
OBJECTIVES: An important factor to take into account when evaluating the effec-
tiveness of a drug is adherence. Adherence describes the degree to which a patient
correctly follows medical advice. The objective of this study was to evaluate the
factors that determine adherence of adult patients with type 2 diabetes treated
with once-daily injectable liraglutide 1.8mg or twice-daily injectable exenatide
10g.METHODS:A retrospective study was conducted employing US data from the
IMS PharMetrics claims database. The index period ranged from January 2010 to
December 2010 and patients needed to be continuously enrolled 12 months before
and after the index date. Patients were treatment naïve to liraglutide and exenatide
but may not have been injection-naïve as prior insulin use was not part of the
patient selection exclusion criteria, which may have impacted the outcomes as a
limitation of the study. Adherence was measured by continuous Medication Pos-
session Ratio (MPR) as well as a categorical response using MPR (MPR80%high
adherence and MPR80%low adherence). The determinants of adherence were
estimated using multivariable models and bivariate testing was conducted for se-
lection of the possible predictors. Covariates were then included and a stepwise
model-building approach was used. RESULTS: Data from 3623 patients (2036 lira-
glutide 1.8mg and 1587 exenatide 10g) were used in the analyses. When adjusting
for confounding effects, patients treated with exenatide 10g were approximately
11% (p.0001) less adherent than patients treated with liraglutide 1.8mg assessed
by the continuous MPR measure. The odds ratio (OR) for achieving a high categor-
ical MPR for liraglutide 1.8mg compared to exenatide 10g was 1.33 in favor of
liraglutide 1.8mg (p.0001). Variables found to impact the level of adherence were
age, gender, the geographic region, treatment, and percentage co-payment from
the claimant. CONCLUSIONS: The analysis showed that once-daily liraglutide
1.8mg is associated with better adherence than twice-daily exenatide 10g.
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OBJECTIVES: To assess the differences in the compliance of Greek patients suffer-
ing from Type 2 diabetes mellitus who receive free combination therapy of met-
formin and vildagliptin compared to the diabetic patients who receive fixed com-
bination therapy of metformin/vildagliptin. METHODS: Eight hundred adult
patients inadequately controlled on twice daily 850mg metformin monotherapy
who were recently added vildagliptin treatment as add on to metformin (fixed dose
combination or free combination) were enrolled in the study. The observation
period was 6 months. Upon treatment initiation each patient received a diary, in
which they had to record their treatment on a daily basis. The diary then was
returned to the physician at the final visit. Additionally, at baseline and at the last
visit of the study, patients were asked to complete a questionnaire related to their
compliance of their indicated treatment. Patients were defined as compliant when
they hadn’t missed any drug dose, received the correct dosage of the medication
and did not interrupt their treatment.RESULTS:The preliminary results the overall
study sample 63% were considered to be compliant. In the between groups analy-
sis, it was found that 56% of patients receiving free combination were compliant
with their treatment compared to a substantially higher 68% of compliant patients
in the fixed combination group (p0,005). Odds Ratio was equal to 1,647, suggesting
that patients receiving free combination were 1.647 times more likely not to com-
ply with their treatment than the patients on fixed combination. A statistically
significant reduction in Hb1Ac was observed in both groups between the first and
last visit (p0,001) but not any difference between two groups, which is attributed
to the short follow-up period. CONCLUSIONS: Patients on fixed dose combination
treatment for Type II Diabetes are more compliant than patients on free dose
combinations. Improved compliance has been shown to improve disease manage-
ment, which can prevent expensive complications.
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OBJECTIVES: Cost-utility analysis of type 2 diabetes mellitus (T2DM) interventions
requires the estimation of utility values. To increase the robustness of such esti-
mates in line with the National Institute for Health and Clinical Excellence (NICE)
requirements a systematic literature review of utility values associated with
T2DM-related complications was performed. METHODS: The review was per-
formed according to NICE methodology recommendations using Medline, Embase,
EconLIT and the NHS Economic Evaluation Database in May 2012. Health utilities
selected were based on the NICE reference case, including a preference for EQ-5D
data and UK population. Landmark study articles reporting multiple utility values
were favoured. RESULTS: A total of 16,578 records were identified. 61 full text
articles were included in the qualitative synthesis. T2DM without complication
values ranged from 0.690 to 0.970. The proposed utility set primarily consisted of
utility values extracted from Clarke 2002 (T2DM without complication: 0.785, myo-
cardial infarction:-0.055, angina:-0.090, heart failure: -0.108, stroke: -0.164, severe
vision loss: -0.074, amputation: -0.28) and Bagust 2005 (peripheral vascular disease:
-0.061, protenuria: -0.048, neuropathy: -0.084, foot ulcer: -0.170 and overweight:
-0.0061 per BMI unit above 25 kg/m2). These values were supplemented by Was-
serfallen 2004 (haemodialysis: 0.621, peritoneal dialysis: 0.581); Kiberd and Jidal
1995 (renal transplant: 0.762); Fenwick (mild non-proliferative diabetic retinopathy
or macular oedema: 0.760, vision threatening diabetic retinopathy: 0.730) as well as
Currie 2006 (major hypoglycaemia: -0.270, minor hypoglycaemia: -0.070). Limita-
tions included the partial lack of studies in a diabetic- or UK-specific population,
the variability in reporting media, mean or values adjusted for confounding factors.
CONCLUSIONS: This set of values should improve the robustness of T2DM modelling
outcomes in line with NICE requirements. Future research could focus on eliciting a
coherent set of values for T2DM-related complications in line with the NICE reference
case and to define the variance around the utility value point estimates.
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OBJECTIVES: To examine the reliability and validity of the Injection Pen Assess-
ment Questionnaire (IPAQ) in a European population. METHODS: The IPAQ is a
29-item measure of objective and comparative ease of use and preference for re-
combinant human growth hormone (rhGH) injection devices based on content
elicited from focus groups and one-on-one interviews of device users. The IPAQ
was included in a Phase 3, open-label, multicenter trial in 136 experienced rhGH
subjects (parent-child dyads) in the United States to test the ease of use and pref-
erence for a new Genotropin® disposable pen (NCT00965484). IPAQ content was
adapted for use in adults and translated into seven languages. Data from a Phase 3,
open-label, multicenter, crossover study (NCT01112865; N120) was used to eval-
uate the psychometric properties of the IPAQ in a mixed sample of dyadic pairs,
adult subjects and caregivers of pediatric subjects. Analyses were conducted by
group and total sample. RESULTS: Confirmatory factor analysis provided evidence
for a second order factor solution for four subscales and a total IPAQ score; and
supported the conceptual framework developed from previous qualitative and
quantitative research. Although IPAQ subscales did not consistently meet accept-
able internal consistency reliability for some group level comparisons, the total
IPAQ score showed high internal consistency for both pens (Cronbach’s alpha 
0.77 – 0.86). In general, the construct validation (predictive validity) findings were
consistent across pens and across subject groups and generally consistent with
those from the US trial. CONCLUSIONS: The IPAQ total score for ease of use dem-
onstrated good internal consistency reliability and good construct validity in mea-
suring ease of use with injection pens to administer rhGH. Findings from this
research are consistent with those from the US-based study, supporting the use-
fulness of the IPAQ total score in evaluating ease of use and preference for injection
pens in clinical trials and in practice.
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OBJECTIVES: There are no existing patient reported outcome (PRO) measures in
Type 2 Diabetes Mellitus (T2DM) developed in accordance with FDA Guidance on
PROs. The objective of this study was to develop and validate a T2DM-specific PRO
measure examining hypoglycemic symptoms (HS), weight neutrality (WN), medi-
cation tolerability (MT), and medication compliance (MC). METHODS: The Diabe-
tes-Management and Impact Questionnaire (D-MIQ) and the Diabetes-Assessment
of Blood Sugar Questionnaire (D-ABS) were developed in three phases: concept
elicitation (CE; n20), item generation, and cognitive interviews (CIs; n20). The
D-ABS was finalized as a 36-item PRO assessing HS with a yes/no response scale
measuring symptom frequency and an 11-point numeric response scale measuring
symptom severity. The D-MIQ was finalized as an 18-item PRO measuring impacts
of HS, WN, MT, and MC, with four- and five-point Likert-type response scales and a
yes/no scale. Following content validation, a stand-alone observational study was
conducted in 100 subjects to assess the psychometric properties of the D-MIQ and
D-ABS. RESULTS: Subjects had a mean age of 57.4 (SD 12.6) years (52% female, 60%
white). All items on the D-ABS and D-MIQ showed good convergent validity with
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